Broadly reactive antibodies specific for Plasmodium falciparum MSP-1 19 are associated with the protection of naturally exposed children against infection

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Dent, Arlene E ^a,b   Moormann, Ann M ^c   Yohn, Christopher T ^a   Kimmel, Rhonda J ^a   Sumba, Peter O ^d   Vulule, John ^d   Long, Carole A ^e   Narum, David L ^e   Crabb, Brendan S ^f   Kazura, James W ^a   Tisch, Daniel J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f BURNET INSTITUTE   (Australia)

Author keywords

Antibodies; Children; Malaria infection; Merozoite surface protein; Plasmodium falciparum

Indexed keywords

MEROZOITE SURFACE PROTEIN 1;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FOLLOW UP; HAPLOTYPE; HUMAN; MALARIA FALCIPARUM; POLYMERASE CHAIN REACTION; SEROLOGY;

ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; CHILD; HAPLOTYPES; HUMANS; IMMUNOGLOBULIN G; KENYA; MALARIA, FALCIPARUM; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PLASMODIUM FALCIPARUM; YOUNG ADULT;

EID: 84865074470     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-287     Document Type: Article

References (45)

1. Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets. Blackman MJ, Curr Drug Targets 2000 1 59 83 10.2174/1389450003349461 11475536
2. A malaria merozoite surface protein (MSP1)-structure, processing and function. Holder AA, Blackman MJ, Burghaus PA, Chappel JA, Ling IT, McCallum-Deighton N, Shai S, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 37 42 1343798
3. A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. Howell SA, Well I, Fleck SL, Kettleborough C, Collins CR, Blackman MJ, J Biol Chem 2003 278 23890 23898 10.1074/jbc.M302160200 12686561
4. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH, Weiss W, Nahlen BL, Kaslow DC, Lal AA, J Immunol 1995 154 6022 6030 7538540
5. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, Sakihama N, Bojang KA, Oduola AM, Kremsner PG, Arnot DE, Greenwood BM, McBride JS, Nat Med 2000 6 689 692 10.1038/76272 10835687
6. Plasmodium falciparum: allelic variation in the merozoite surface protein 1 gene in wild isolates from southern Vietnam. Kaneko O, Kimura M, Kawamoto F, Ferreira MU, Tanabe K, Exp Parasitol 1997 86 45 57 10.1006/expr.1997.4147 9149240
7. Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum. Kang Y, Long CA, Mol Biochem Parasitol 1995 73 103 110 10.1016/0166-6851(95) 00102-7 8577318
8. Identification of frequently recognized dimorphic T-cell epitopes in Plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. Lee EA, Flanagan KL, Odhiambo K, Reece WH, Potter C, Bailey R, Marsh K, Pinder M, Hill AV, Plebanski M, Am J Trop Med Hyg 2001 64 194 203 11442217
9. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA, J Exp Med 1994 180 389 393 10.1084/jem.180.1.389 7516416
10. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. Chang SP, Gibson HL, Lee-Ng CT, Barr PJ, Hui GS, J Immunol 1992 149 548 555 1624802
11. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, Nwagwu M, Infect Immun 2002 70 5328 5331 10.1128/IAI.70.9.5328-5331. 2002 12183594
12. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA, Am J Trop Med Hyg 1998 58 211 219 9502606
13. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, Milligan P, Bosomprah S, Chilengi R, Osei YD, Akanmori BD, Theisen M, Malar J 2008 7 142 10.1186/1475-2875-7-142 18664257
14. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM, J Infect Dis 1996 173 765 769 10.1093/infdis/173.3.765 8627050
15. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, Lowe B, Mwangi T, Bull PC, Thomas AW, Cavanagh DR, McBride JS, Lanar DE, Mackinnon MJ, Conway DJ, Marsh K, Infect Immun 2008 76 2240 2248 10.1128/IAI.01585-07 18316390
16. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG, Infect Immun 2009 77 1165 1174 10.1128/IAI.01129-08 19139189
17. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. Fowkes FJ, Richards JS, Simpson JA, Beeson JG, PLoS Med 2010 7 1000218 10.1371/journal.pmed.1000218 20098724
18. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. John CC, O'Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, Kazura JW, Crabb BS, J Immunol 2004 173 666 672 15210830
19. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM, Infect Immun 2004 72 1557 1567 10.1128/IAI.72.3.1557-1567.2004 14977962
20. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, Martin LB, Saul AJ, Miller LH, Long CA, Infect Immun 2006 74 4573 4580 10.1128/IAI.01679-05 16861644
21. Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus. Hui GS, Hashiro C, Nikaido C, Case SE, Hashimoto A, Gibson H, Barr PJ, Chang SP, Infect Immun 1993 61 3403 3411 7687586
22. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR, PLoS One 2009 4 4708 10.1371/journal.pone.0004708 19262754
23. A polymerase chain reaction/ligase detection reaction fluorescent microsphere assay to determine Plasmodium falciparum MSP-119 haplotypes. Dent AE, Yohn CT, Zimmerman PA, Vulule J, Kazura JW, Moormann AM, Am J Trop Med Hyg 2007 77 250 255 17690395
24. Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen. Qari SH, Shi YP, Goldman IF, Nahlen BL, Tibayrenc M, Lal AA, Mol Biochem Parasitol 1998 92 241 252 10.1016/S0166-6851(98)00010-3 9657329
25. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Kaslow DC, Hui G, Kumar S, Mol Biochem Parasitol 1994 63 283 289 10.1016/0166-6851(94)90064-7 7516493
26. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. John CC, Moormann AM, Pregibon DC, Sumba PO, McHugh MM, Narum DL, Lanar DE, Schluchter MD, Kazura JW, Am J Trop Med Hyg 2005 73 222 228 16014863
27. Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, Johnson AH, Clin Vaccine Immunol 2006 13 1307 1313 10.1128/CVI.00183-06 17035513
28. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. Piriou E, Kimmel R, Chelimo K, Middeldorp JM, Odada PS, Ploutz-Snyder R, Moormann AM, Rochford R, J Med Virol 2009 81 1088 1093 10.1002/jmv.21485 19382256
29. Temporal stability of naturally acquired immunity to Merozoite Surface Protein-1 in Kenyan adults. Dent AE, Chelimo K, Sumba PO, Spring MD, Crabb BS, Moormann AM, Tisch DJ, Kazura JW, Malar J 2009 8 162 10.1186/1475-2875-8-162 19607717
30. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. O'Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, Crabb BS, J Exp Med 2001 193 1403 1412 10.1084/jem.193.12.1403 11413195
31. Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst-thiazole orange staining strategy. Grimberg BT, Erickson JJ, Sramkoski RM, Jacobberger JW, Zimmerman PA, Cytometry A 2008 73 546 554 18302186
32. Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. Dent A, Malhotra I, Mungai P, Muchiri E, Crabb BS, Kazura JW, King CL, J Immunol 2006 177 7139 7145 17082631
33. Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, Kone AK, Traore K, Ouattara A, Djimde AA, Sehdev PS, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, PLoS Med 2007 4 93 10.1371/journal.pmed.0040093 17355170
34. Sequence diversity and evolution of the malaria vaccine candidate merozoite surface protein-1 (MSP-1) of Plasmodium falciparum. Ferreira MU, Ribeiro WL, Tonon AP, Kawamoto F, Rich SM, Gene 2003 304 65 75 12568716
35. Allelic recombination and linkage disequilibrium within Msp-1 of Plasmodium falciparum, the malignant human malaria parasite. Sakihama N, Kimura M, Hirayama K, Kanda T, Na-Bangchang K, Jongwutiwes S, Conway D, Tanabe K, Gene 1999 230 47 54 10.1016/S0378-1119(99)00069-4 10196473
36. Non-variant specific antibody responses to the C-terminal region of merozoite surface protein-1 of Plasmodium falciparum (PfMSP-1(19)) in Iranians exposed to unstable malaria transmission. Zakeri S, Mehrizi AA, Zoghi S, Djadid ND, Malar J 2010 9 257 10.1186/1475-2875-9-257 20846388
37. Genetic diversity and dynamics of Plasmodium falciparum and P. vivax populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea. Bruce MC, Galinski MR, Barnwell JW, Donnelly CA, Walmsley M, Alpers MP, Walliker D, Day KP, Parasitology 2000 121 Pt 3 257 272 11085246
38. Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles. Farnert A, Lebbad M, Faraja L, Rooth I, Malar J 2008 7 241 10.1186/1475-2875-7-241 19025582
39. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Farnert A, Snounou G, Rooth I, Bjorkman A, Am J Trop Med Hyg 1997 56 538 547 9180605
40. Diversity of Plasmodium falciparum clones infecting children living in a holoendemic area in north-eastern Tanzania. Magesa SM, Mdira KY, Babiker HA, Alifrangis M, Farnert A, Simonsen PE, Bygbjerg IC, Walliker D, Jakobsen PH, Acta Trop 2002 84 83 92 10.1016/S0001-706X(02)00179-1 12429425
41. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K, Lefevre G, De Palacios PI, Genton B, Am J Trop Med Hyg 2008 78 241 247 18256423
42. Understanding the pharmacokinetics of Coartem. Djimde A, Lefevre G, Malar J 2009 8 Suppl 1 4 10.1186/1475-2875-8-S1-S4 19917074
43. Treatment with coartem (artemether-lumefantrine) in Papua New Guinea. Schoepflin S, Lin E, Kiniboro B, DaRe JT, Mehlotra RK, Zimmerman PA, Mueller I, Felger I, Am J Trop Med Hyg 2010 82 529 534 10.4269/ajtmh.2010.09-0334 20348494
44. Multiple Plasmodium falciparum infections in Tanzanian infants. Felger I, Smith T, Edoh D, Kitua A, Alonso P, Tanner M, Beck HP, Trans R Soc Trop Med Hyg 1999 93 Suppl 1 29 34 10450423
45. Novel Plasmodium falciparum clones and rising clone multiplicities are associated with the increase in malaria morbidity in Ghanaian children during the transition into the high transmission season. Ofosu-Okyere A, Mackinnon MJ, Sowa MP, Koram KA, Nkrumah F, Osei YD, Hill WG, Wilson MD, Arnot DE, Parasitology 2001 123 113 123 11510676